Skip to main content

Bryhali FDA Approval History

Last updated by Judith Stewart, BPharm on Nov 13, 2018.

FDA Approved: Yes (First approved November 6, 2018)
Brand name: Bryhali
Generic name: halobetasol propionate
Dosage form: Lotion
Previous Name: Jemdel
Company: Ortho Dermatologics
Treatment for: Plaque Psoriasis

Bryhali (halobetasol propionate) is a high-potency topical corticosteroid formulation for the treatment of plaque psoriasis in adults.

DOSAGE AND ADMINISTRATION

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Development timeline for Bryhali

DateArticle
Nov  7, 2018Approval Bausch Health Announces U.S. Launch of Bryhali (halobetasol propionate) Lotion, 0.01%, for Plaque Psoriasis In Adults
Oct  9, 2018Bausch Health's Bryhali (halobetasol propionate) Lotion, 0.01%, Receives Tentative FDA Approval For Plaque Psoriasis In Adults
Feb 14, 2018Ortho Dermatologics Announces U.S. FDA Filing Acceptance for Jemdel Plaque Psoriasis Treatment

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.